ACM
ABBV icon

Asymmetry Capital Management’s AbbVie ABBV Stock Holding History

Asymmetry Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$12.8M Buy
+94,448
New +$11.2M 6.79% 4
2020
Q1 		– Sell
-18,921
Closed -$1.68M – 30
2019
Q4 		$1.68M Buy
+18,921
New +$1.57M 3% 14
2019
Q3 		– Sell
-14,406
Closed -$1.05M – 23
2019
Q2 		$1.05M Buy
+14,406
New +$1.13M 0.57% 27

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Asymmetry Capital Management's ABBV Position: Q4 2021 in Review

Asymmetry Capital Management opened a new position in AbbVie (ABBV) in Q4 2021: 94,448 shares worth $12.8M. The stake represents 6.79% of the portfolio and ranks #4 among its holdings. This is a return to the name: Asymmetry Capital Management previously reported a position in ABBV as recently as Q4 2019.

Asymmetry Capital Management first reported a position in ABBV in Q2 2019 and has held it in 3 quarters since. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.

  • Asymmetry Capital Management held 94,448 shares of AbbVie worth $12.8M as of Q4 2021.
  • AbbVie was a new Asymmetry Capital Management position in Q4 2021.
  • AbbVie made up 6.79% of Asymmetry Capital Management's portfolio in Q4 2021, its #4 holding.
  • Asymmetry Capital Management first reported a position in AbbVie in Q2 2019 and has held it in 3 quarters since.
  • 2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.